Alpha 2.0
Login Register
» Authors » Kazuhisa Takahashi

Kazuhisa Takahashi

Explore the profile of Kazuhisa Takahashi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 906
Citations 12139
Followers 0
Related Specialties
Orthopedics
Oncology
General Medicine
Top 10 Co-Authors
Seiji Ohtori
Sumihisa Orita
Yasuchika Aoki
Kazuyo Yamauchi
Gen Inoue
Yawara Eguchi
Miyako Suzuki
Masayuki Miyagi
Junichi Nakamura
Kazuhide Inage
Published In
Spine (Phila Pa 1976)
J Orthop Sci
Eur Spine J
Asian Spine J
Respir Investig
Affiliations
Soon will be listed here.
Recent Articles
1.
Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma
Torasawa M, Yoshida T, Shiraishi K, Yagishita S, Ono H, Uehara Y, et al.
Lung Cancer . 2025 Mar; 202:108494. PMID: 40088580
Background: In EGFR-mutated lung adenocarcinoma (EGFRm LUAD), EGFR mutations do not necessarily result in increased EGFR expression (EGFR-exp), which differs among patients. However, the factors influencing EGFR-exp and the impact...
2.
Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial
Shukuya T, Asao T, Goto Y, Mimori T, Takayama K, Kaira K, et al.
Lancet Oncol . 2025 Mar; 26(3):331-342. PMID: 40049197
Background: Despite the poor prognosis of advanced or recurrent thymic carcinoma, the rarity of thymic carcinoma has delayed the development and introduction of novel pharmacotherapy options. Carboplatin plus paclitaxel remains...
3.
Novel Approach to Overcome Osimertinib Resistance Using Bromodomain and Extra-Terminal Domain Inhibitors
Miyashita Y, Tajima K, Izumi K, Matsumoto N, Hayakawa D, Nakamura I, et al.
Cancer Sci . 2025 Mar; PMID: 40036147
Osimertinib, a third-generation EGFR-tyrosine kinase inhibitor, is the first-line therapy for lung cancer harboring EGFR mutations. The mechanisms underlying osimertinib resistance are diverse, with approximately half remaining unknown. Epigenetic dysregulation...
4.
Elevated mepolizumab levels in patients with severe asthma responsive to 1 year's mepolizumab treatment
Nishimaki T, Sasano H, Harada S, Takeshige T, Sandhu Y, Tanabe Y, et al.
J Allergy Clin Immunol Glob . 2025 Feb; 4(2):100410. PMID: 39974310
Background: Asthma involves variable airflow limitation and persistent airway inflammation. Eosinophilic asthma, characterized by cytokine-mediated type 2 inflammation, is generally treated with inhaled corticosteroids. However, patients with severe asthma may...
5.
Survival benefit and potential markers of chemotherapy for elderly and poor performance status patients with advanced non-small cell lung cancer: Results from the Japanese Joint Committee of lung cancer registry database
Ikeda S, Ogura T, Miyaoka E, Sekine I, Shukuya T, Takayama K, et al.
Lung Cancer . 2025 Feb; 200:108102. PMID: 39924255
Introduction: Data on chemotherapy for elderly, poor performance status (PS) non-small cell lung cancer (NSCLC) are clinically important but insufficient due to their exclusion from most interventional studies. This study...
6.
Evaluating the Diagnostic Value of Lymphocyte Subsets in Bronchoalveolar Lavage Fluid and Peripheral Blood Across Various Diffuse Interstitial Lung Disease Subtypes
Harada S, Kato M, Nakagome K, Sasano H, Tanabe Y, Takeshige T, et al.
Biomolecules . 2025 Jan; 15(1). PMID: 39858516
Diffuse interstitial lung diseases (ILD) include conditions with identifiable causes such as chronic eosinophilic pneumonia (CEP), sarcoidosis (SAR), chronic hypersensitivity pneumonitis (CHP), and connective tissue disease-associated interstitial pneumonia (CTD), as...
7.
Atypical Adult-Onset IgA Vasculitis With Extremely Rare Complications Including Diffuse Alveolar Hemorrhage, Heart Failure, and Stroke
Motojima M, Tanabe Y, Makino F, Suzuki H, Tomita S, Sasaki S, et al.
Cureus . 2025 Jan; 16(12):e75607. PMID: 39803030
IgA vasculitis (IgAV) generally occurs in young people and presents with a tetrad of symptoms: purpura, abdominal pain, arthralgia, and nephritis. However, it may have an atypical course without the...
8.
Design of buffer property for the new enrichment method of circulating tumor cell based on immunomagnetic-negative separation
Hoshi K, Hashim Y, Togo S, Saiwaki S, Motomura H, Sumiyoshi I, et al.
Comput Struct Biotechnol J . 2024 Dec; 25:281-289. PMID: 39720309
Metastasis is a significant contributor to cancer-related mortality and a critical issue in cancer. Monitoring the changes in circulating tumor cells (CTCs) with metastatic potential is a valuable prognostic and...
9.
Effective use of dupilumab for eosinophilic gastritis concomitant with severe asthma
Takeshige T, Koyama R, Motomura H, Okajima A, Nishioki T, Watanabe J, et al.
Allergy Asthma Clin Immunol . 2024 Dec; 20(1):68. PMID: 39696614
Background: Eosinophilic gastrointestinal diseases (EGIDs) are chronic immune-mediated inflammatory disorders characterized by gastrointestinal symptoms and eosinophilic inflammation in specific regions of the gastrointestinal tract. "Eosinophilic gastritis" (EoG) refers to the...
10.
Japanese Patients with Severe Asthma Identified as Responders to Omalizumab Treatment at 2 Years Based on the GETE Score Continued Treatment for an Extended Period
Goto A, Harada S, Sasano H, Sandhu Y, Tanabe Y, Abe S, et al.
J Asthma Allergy . 2024 Nov; 17:1173-1186. PMID: 39558969
Purpose: Omalizumab, the anti-IgE monoclonal antibody used to treat severe asthma, reduces asthma exacerbations, hospitalizations, and corticosteroid use. Although allergic asthma is a therapeutic target of omalizumab, omalizumab is not...